Persica bolsters PP353 rationale with disc microbiology review

Persica Pharmaceuticals has published a methodological scoping review arguing that divergent findings in disc microbiology research are largely explained by differences in assay sensitivity, not by genuine variation in bacterial presence. The analysis, submitted to the European Spine Journal and available on its preprint server, is intended to strengthen the scientific rationale for PP353, the company's intradiscal antibiotic candidate for vertebrogenic lumbar back pain (vLBP).

The review examined 22 published culture-based disc microbiology studies and found substantial variation in detection methods. Studies using what the authors characterise as good microbiology practice detected low-bioburden infection in approximately 50% of evaluated discs, with around 80% of those infections attributed to Cutibacterium acnes. Lower-sensitivity methods, by contrast, detected bacteria in as few as 11% of samples that higher-sensitivity methods identified as positive, and in less than 1% of samples when applied to surgically obtained tissue.

The bacterial hypothesis

The findings matter because the scientific premise underpinning PP353 is that a proportion of chronic low back pain cases with Modic type changes visible on MRI are caused by low-grade bacterial infection rather than purely mechanical or degenerative processes. If that hypothesis holds, then a targeted intradiscal antibiotic could address the underlying cause rather than managing symptoms through analgesia or, in more advanced cases, irreversible nerve ablation.

Dr Lloyd Czaplewski, chief scientific officer at Persica, said the analysis "adds further validation to our hypothesis that vertebrogenic Lumbar Back Pain and Modic changes observed in a significant group of patients is caused by low grade bacterial infection, strengthening the scientific rationale for PP353 as a precisely targeted, non-opioid treatment for these patients."

PP353 delivers linezolid, a well-characterised broad-spectrum antibiotic, directly into the affected intervertebral disc via two administrations four days apart. The formulation uses a thermosensitive vehicle that increases in viscosity at body temperature to limit leakage into adjacent tissue. A radio-opaque dye enables image-guided placement confirmation. In a randomised, double-blind, sham-controlled Phase 1b study of 40 participants, the results of which were published in The Lancet's eClinicalMedicine in February 2026, more than 60% of treated patients achieved a pain reduction of 50% or more, with decreased opioid use sustained over 12 months.

Market context and competitive landscape

Chronic low back pain is one of the highest-burden conditions globally by disability-adjusted life years, and vLBP with Modic changes is estimated to affect around 10 million patients in the US and Europe, representing roughly 15% of all chronic low back pain cases. Current standard of care offers limited options: physiotherapy, long-term opioid analgesia, and nerve ablation procedures that are invasive and irreversible. The non-opioid pain space has drawn increasing attention from both regulators and investors following sustained policy pressure to reduce opioid dependency, and the FDA's designation framework for non-opioid alternatives has created a more supportive pathway for novel mechanisms.

No directly comparable intradiscal antibiotic programme is known to be in late-stage development, though a number of university-spinout and early-stage companies are exploring disc microbiome-related interventions. Persica remains a privately held, clinical-stage company actively seeking a strategic partner or investor to fund a registrational Phase 3 programme. The publication of this scoping review, while itself a methodological rather than clinical contribution, serves a clear business development purpose: it addresses a principal scientific objection to the bacterial-infection hypothesis that sceptical partners and regulators are likely to raise.

The next meaningful milestone for Persica will be either securing a partnering or financing agreement, or announcing a Phase 3 design and regulatory engagement timeline.